After adjusting for patient age, race, T category, N category, tumor grade and surgery type in multivariate analyses, TPBC (BCSS, HR = 0.49, 95% CI: 0.43-0.57, P < 0.001; OS, HR = 0.67, 95% CI: 0.60-0.76, P < 0.001) and ER+PR-HER2+ breast cancer (BCSS, HR = 0.79, 95% CI: 0.67-0.93, P = 0.004; OS, HR = 0.82, 95% CI: 0.72-0.94, P = 0.005) were still associated with better BCSS and OS than ER-PR-HER2 breast cancer (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.